{"url":"https://newsforagent.com/news/2026-11-17/racura-oncology-rc220-bisantrene-equivalence","markdown_url":"https://newsforagent.com/news/2026-11-17/racura-oncology-rc220-bisantrene-equivalence.md","title":"Racura Oncology Shows RC220 Matches RC110 Exposure","headline":"Racura Oncology's RC220 Reformulation Matches RC110 Drug Exposure in Canine Study","description":"Racura Oncology's RC220 bisantrene formulation met the 0.80 to 1.25 equivalence range against RC110 in a canine study.","section":"Research & Clinical Trials","published_at":"2026-11-17T02:14:50+00:00","modified_at":"2026-11-17T02:14:50+00:00","author":"News Desk","key_takeaways":["Racura Oncology reported that RC220 peak and total exposure ratios fell within the 0.80 to 1.25 equivalence range against RC110 in male canines.","RC110 was approved in France in 1988 for relapsed or refractory acute myeloid leukaemia and produced a 40% response rate in two Phase 2 trials.","Racura plans to evaluate RC220 in a Phase 2b/3 EMILI trial in AML, alongside the HARNESS lung cancer and CPACS solid tumour programmes."],"companies":[{"name":"Racura Oncology","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00yhod9/racura-oncology","website":"https://www.racuraoncology.com"}],"source":{"publisher":"TradingView","title":"Racura Oncology Demonstrates Key Equivalence for Reformulated Bisantrene Anti-Cancer Drug","url":"https://www.tradingview.com/news/smallcaps:0392ae92e094b:0-racura-oncology-demonstrates-key-equivalence-for-reformulated-bisantrene-anti-cancer-drug/"},"other_sources":[],"tags":["Research & Clinical Trials","Racura Oncology"],"body_markdown":"Racura Oncology said its reformulated bisantrene drug RC220 showed pharmacokinetic equivalence to the older RC110 formulation in a non-clinical bridging study on male canines, with peak and total exposure ratios inside the 0.80 to 1.25 range. The Australian clinical-stage oncology company announced the results on November 17, [TradingView](https://www.tradingview.com/news/smallcaps:0392ae92e094b:0-racura-oncology-demonstrates-key-equivalence-for-reformulated-bisantrene-anti-cancer-drug/) reported.\n\n## What the RC220 Bridging Study Found\n\n[Racura Oncology](https://akta.pro/company-profiles/00yhod9/racura-oncology) develops (E,E)-bisantrene, a small-molecule anti-cancer agent that stabilises G4-DNA and RNA structures and inhibits the c-MYC gene, which the company says is dysregulated in up to 70% of all cancers. RC220 contains the same active pharmaceutical ingredient as RC110 but different non-drug ingredients, and is designed for peripheral intravenous delivery in the arm or leg rather than requiring a central line.\n\nThe study compared systemic drug exposure between the two formulations. Ratios of peak and total exposure for RC220 fell within the pre-specified 0.80 to 1.25 range, the standard regulatory benchmark for bioequivalence between formulations. Racura said the result supports using the RC110 clinical dataset and dosing levels in RC220's development, including a planned Phase 2b/3 EMILI trial in acute myeloid leukaemia.\n\nRC110 has an extensive clinical history and was approved in France in 1988 for relapsed or refractory AML. Chief executive Dr Daniel Tillett said: \"The results showed the two formulations delivered equivalent exposure to (E,E)-bisantrene, providing an important bridge to the clinical experience with RC110 that produced a 40% response rate in two separate Phase 2 trials in heavily pre-treated AML patients.\" Tillett added that the study supports plans to evaluate RC220 in the EMILI trial as well as in the HARNESS lung cancer and CPACS solid tumour programmes.\n\n## Racura's Funding and Patent Record\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Racura raised A$3.22 million in a private placement in December 2025 led by Executive Chair Dr Peter Smith to fund the HARNESS-1 Phase 1a/b clinical trial, supplementing an A$5.25 million FY2024 R&D tax rebate. The same records show the company filed new composition of matter patent claims in October 2025 covering the G4-DNA/RNA binding mechanism of (E,E)-bisantrene, providing up to 20 years of IP protection.\n\n## Earlier RC220 Trial Milestones\n\nRacura dosed the first patient in the Phase Ia/b HARNESS-1 trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer in June 2026, Clinical Trials Arena reported. The patient received RC220 at 50 mg/m2 intravenously with no adverse events observed, according to Aijourn. PR Newswire APAC reported the dosing took place at Monash Health in Victoria, Australia.\n\n## Racura's November 23 AGM\n\nRacura set its annual general meeting for November 23, 2026, with a director-nomination deadline as the only shareholder lever, AInvest reported.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}